# Study Of ATRN-119 In Patients With Advanced Solid Tumors

> **NCT04905914** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Aprea Therapeutics** · enrollment: 132 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** ATRN-119

## Key facts

- **NCT ID:** NCT04905914
- **Lead sponsor:** Aprea Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-09
- **Primary completion:** 2028-02
- **Final completion:** 2028-02
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04905914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04905914, "Study Of ATRN-119 In Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04905914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*